[OFER-TRABEC] NAC: Postdoctoral position - Juan de la Cierva

------------------------
(c)OFER-TRABEC es un servicio ofrecido por RedIRIS (Red española para la investigación)
(Permitida la reproducción siempre que se cite la fuente de este Servicio).
*************************
Bolsas de empleo:
http://www.biocat.cat/es/bolsa-de-empleo
------------------------

---Procedencia:
Institución:Vall d'Hebron Research Institute, Barcelona
Contacto correo-e:molecular.oncology@vhir.org
---
POSTDOCTORAL POSITION – JUAN DE LA CIERVA

We are currently looking for a highly motivated postdoctoral candidate to apply for a Juan de la Cierva position funded by the Spanish Government. The successful candidate will join the group of Biomedical Research in Digestive Tumors at the Vall d'Hebron Research Institute (http://www.vhir.org/gr/nanomolecularoncology), and will work on an established research line (http://bit.ly/1woSHyG) focusing on the role of the small GTPase RHOA in gastric cancer and the characterization of the underlying molecular mechanisms. The project will involve the use of a variety of cell/molecular biology techniques including in vitro systems, animal models and large tumor collections.

THE CANDIDATES MUST:

- Have a PhD in biosciences (obtained after January 2014 or between January 2011 and December 2013).
- Have experience in cancer research, preferably on gastric and/or colorectal tumors.
- Be fluent in English.
- Fulfill all the requirements to apply for a junior or senior Juan de la Cierva position: http://ow.ly/Wb351 and http://ow.ly/Wb3c1.

WE OFFER:

- Postdoctoral position for two years
- The gross salary will be euros 21,500 or 25,000 euros per year, for the Junior and Senior categories, respectively.
- Dynamic and stimulating research environment.

CONTACT:

Send a copy of your CV, a cover letter and the contact of three referees before the 25th of January 2016 to molecular.oncology@vhir.org. Reference JDC2016.


----------------
Información complementaria de la oferta:
SELECTED PUBLICATIONS

Fernando Cartón-García, Arend Overeem, Rocio Nieto, Sarah Bazzocco, Higinio Dopeso, Irati Macaya, Josipa Bilic, Stefania Landolfi, Javier Hernandez-Losa, Simo Schwartz Jr, Santiago Ramon y Cajal, Sven C. D. van Ijzendoorn and Diego Arango. Myo5b knockout mice as a model of microvillus inclusion disease. 2015 Scientific Reports, in press.

Fernández Y, Foradada L, García-Aranda N, Mancilla S, Suárez-López L, Céspedes MV, Herance JR, Arango D, Mangues R, Schwartz S and Abasolo IBioluminescent Imaging of Animal Models for Human Colorectal Cancer Tumor Growth and Metastatic Dissemination to Clinically Significant Sites. Journal of Molecular Biology and Molecular Imaging 2015 in press

Sarah Bazzocco, Elena Andretta, Paulo Rodrigues, Miriam Garrido, Hafid Alazzouzi, Fiona Chionh, Fernando Carton-Garcia, Irati Macaya, Rocio Nieto, Alex Sanchez, Simo Schwartz Jr, Higinio Dopeso, Josipa Bilic, John M. Mariadason, Diego Arango. Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment. 2015 Clinical Cancer Research May 5. [Epub ahead of print]

Acun T, Demir K, Oztas E, Arango D & Yakicier MC. PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas. OMICS. 2015 Apr;19(4):220-229- (Impact Factor: 2.7)

Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, Mateo-Lozano S, Bilić J, Cartón-García F, Nieto R, Suárez-López L, Afonso E, Landolfi S, Hernandez-Losa J, Kobayashi K, Cajal SR, Tabernero J, Tebbutt NC, Mariadason JM, Schwartz S Jr, Arango D. RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. Nature Communications. 2014 Nov 21;5:5458. - (Impact Factor: 10.7)

Shin J, Carr A, Corner GA, Tögel L, Dávaos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM. The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner. J Biol Chem. 2014 Sep 5;289(36):25306-16. - (Impact Factor: 5.3)

Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014 Apr 22. [Epub ahead of print] - (Impact Factor: 9.2)

Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Cajal SR, Mooseker MS, Mariadason JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Jr SS, Arango D. Brush border myosin Ia inactivation in gastric but not endometrial tumors. Int J Cancer. 2013 Apr 15;132(8):1790-9. - (Impact Factor: 5.4)

Dávalos V, Súarez-López L, Castaño J, Messent A, Abasolo I, Fernandez Y, Guerra-Moreno A, Espín E, Armengol M, Musulen E, Ariza A, Sayós J, Arango D, Schwartz S Jr. hSMC, a Core Subunit of Human Condensin Complex, is a Novel Transcriptional Target of the Wnt Signaling Pathway and a New Therapeutic Target. J Biol Chem. 2012 287(52):43472-81 - (Impact Factor: 5.3)

Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM. Villin expression is frequently lost in poorly differentiated colon cancer. Am J Pathol. 2012 Apr;180(4):1509-21 - (Impact Factor: 5.2)

Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón Y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D. Brush border Myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. Epub 2012 Jan 18. - (Impact Factor: 9.8)

Alhopuro P, Sammalkorpi H, Niittymäki I, Biström M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ, Heliövaara E, Puhakka J, Tuupanen S, Sousa S, Seruca R, Ferreira AM, Hofstra RM, Mecklin JP, Järvinen H, Ristimäki A, Orntoft TF, Hautaniemi S, Arango D, Karhu A, Aaltonen LA. Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer. 2012 Apr 1;130(7):1558-66. (Impact Factor: 5.4)

Alhopuro P, Björklund M, Sammalkorpi H, Turunen M, Tuupanen S, Tuupanen S, Biström M, Niittymäki L, Lehtonen H, Kivioja T, Launonen V, Saharinen J, Nousiainen K, Hautaniemi S, Nuorva K, Mecklin JP, Järvinen H, Orntoft T, Arango D, Lehtonen R, Karhu A, Taipale J, Aaltonen LA. Mutations in the Circadian Gene CLOCK in Colorectal Cancer. Molecular Cancer Research 2010 8(7):952-60..- (Impact Factor: 4.5)

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clinical Cancer Research. 2010 Apr 15;16(8):2375-82.- (Impact Factor: 8.7)

Wilson AJ, Chueh AC, Tögel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, Smartt HJ, Murray LB, Nicholas C, Heerdt BG, Arango D, Augenlicht LH, Mariadason JM. Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction. Cancer Research, 2010 Jan 15;70(2):609-20 (Impact Factor: 9.3)

*************************************************************************
Para darse de baja OFER-TRABEC pinche y envíe:
mailto:OFER-TRABEC-signoff-request@listserv.rediris.es
*************************************************************************